Story
Biotech Funding Jumps 75% Year-to-Date, Fueling IPO and M&A Boom

Global biotechnology funding has surged 75% year-to-date through August 7 compared to the same period last year, a dramatic rebound driven by a renewed appetite for public offerings, according to data from Macquarie. This influx of capital is fueling significant dealmaking and successful market debuts across the sector.
Capital Inflows Accelerate
The year-over-year growth was led by a 235% increase in initial public offerings (IPOs) and a 138% rise in follow-on offerings, Macquarie reported. The momentum has been particularly strong in recent weeks. For the four-week period ending August 7, total funding climbed 62% compared to the same period in the prior year, buoyed by a sixfold jump in IPOs and a more than doubling of venture funding.
Investor sentiment has tracked the funding boom, with the XBI biotech index gaining 7% in the week ending August 7 to close at $157.4. This indicates a broader market confidence in the sector's growth prospects and innovation pipeline.
A Flurry of Corporate Activity
The robust funding environment is enabling a wave of corporate activity, from large-scale acquisitions to high-profile public listings. Several major deals were announced, underscoring the trend:
Ad- Braveheart Bio's IPO: The company raised $382.5 million in an upsized Nasdaq IPO. Its shares surged 66% on their August 6 trading debut, with proceeds earmarked for a Phase 3 study of its cardiac myosin inhibitor, BHB-1893.
- Curium to Acquire Lantheus: Curium agreed to buy radiodiagnostics firm Lantheus for up to $8 billion. The deal represents an approximate 29% premium over Lantheus's 30-day average share price and gives Curium control of the prostate cancer imaging drug Pylarify.
- Supernus and Indivior Merger: The two firms agreed to an all-stock merger, creating a company focused on central nervous system (CNS) treatments with projected 2026 sales of $2.2 billion. The combined entity expects $125 million in annual cost savings.
Strategic Deals and Private Equity
Other transactions highlight the sector's dynamism. Tarsus Pharma agreed to acquire Alkeus Pharma for $450 million upfront plus up to $350 million in milestone payments, gaining a Phase 3 oral treatment for Stargardt disease. To support the deal, Tarsus raised $125 million through a PIPE (Private Investment in Public Equity) offering.
Private equity has also shown strong interest. KKR agreed to take medical device contract manufacturer Integer private in an all-cash transaction valued at $5.7 billion. The offer represents a significant 52% premium for Integer shareholders.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.